Stocks
Cell Technologies, Inc.CTIC
HealthcareBiotechnology
A clinical-stage biopharmaceutical company developing small-molecule drugs for oncology and inflammatory diseases. Its lead candidates target kinase pathways, with a focus on acute myeloid leukemia and other hematologic malignancies. Investors track CTIC for its pipeline progress and regulatory milestones.
Congressional Interest in Cell Technologies, Inc. (CTIC)
1 member of Congress has disclosed 1 trade in Cell Technologies, Inc. (CTIC), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1
Who in Congress Is Trading CTIC?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2026-02-17 | Rohit Khanna | sell | $1K-$15K |